✦ LIBER ✦

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)

✍ Scribed by Seok Jin Kim; Chul Won Choi; Yeung-Chul Mun; Sung Yong Oh; Hye Jin Kang; Soon Il Lee; Jong Ho Won; Min Kyoung Kim; Jung Hye Kwon; Jin Seok Kim; Jae-Yong Kwak; Jung Mi Kwon; In Gyu Hwang; Hyo Jung Kim; Jae Hoon Lee; Sukjoong Oh; Keon Woo Park; Cheolwon Suh; Won Seog Kim

Book ID: 119897171
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 548 KB
Volume: 11
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-11-321

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic factors in primary diffuse la

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

✍ Yu Ri Kim, Jin Seok Kim, Yoo Hong Min, Dok HyunYoon, Ho-Jin Shin, Yeung-Chul Mun 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 363 KB

Therapy for non-Hodgkin lymphoma in chil

Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials

✍ Seidemann, Kathrin; Tiemann, Markus; Henze, G�nter; Sauerbrey, Axel; M�ller, Sus 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views

Background. Non-Hodgkin lymphomas (NHL) represent an important complication of primary immunodeficiency (ID), posing new therapeutic challenges in this patient population. This study analyzes clinical data and therapy results of pediatric patients with primary ID and NHL in three consecutive NHL-BFM

Different age limits for elderly patient

Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age : Analysis of a population-based non-Hodgkin lymphoma registry

✍ Eduard Maartense; Hanneke C. Kluin-Nelemans; Saskia le Cessie; Philip M. Kluin; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 3 views

High-Dose Etoposide Plus Granulocyte Col

High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma Previously Treated with CHOP-based Chemotherapy: A Study from the Consortium for Improving Survival of Lymphoma

✍ Hyun, Shin Young; Cheong, June-Won; Kim, Soo-Jeong; Min, Yoo Hong; Yang, Deok-Hw 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 260 KB

Multivariate analysis of febrile neutrop

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study

✍ Ruth Pettengell; André Bosly; Thomas D. Szucs; Christian Jackisch; Robert Leonar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

High dose therapy may have no survival b

High dose therapy may have no survival benefit over CHOEP primary chemotherapy for people with aggressive non-Hodgkin’s lymphoma: Abstracted from: Kaiser U, Uebelacker I, Birkmann U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. Journal of Clinical Oncology 2002; 20: 4413–19

✍ Axel Glasmacher 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 80 KB